Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNSNYSE:ENOVNASDAQ:ESTANYSE:SNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.15-1.0%$12.46$11.75▼$25.36$567.41M1.14379,616 shs355,836 shsENOVEnovis$32.28+0.5%$33.07$28.83▼$49.83$1.84B1.71844,788 shs1.04 million shsESTAEstablishment Labs$40.84+8.9%$35.18$26.56▼$52.41$1.08B0.74470,783 shs649,983 shsSNNSmith & Nephew SNATS$30.20+1.0%$28.58$23.69▼$31.72$13.10B0.68812,146 shs853,866 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL-0.86%+0.56%-5.04%-12.97%-36.68%ENOVEnovis+0.34%+5.18%-3.47%-14.46%-28.39%ESTAEstablishment Labs+8.91%+7.39%+10.68%+1.01%-6.31%SNNSmith & Nephew SNATS+1.00%+5.87%+4.53%+7.75%+21.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAVANOS MEDICAL1.7364 of 5 stars0.03.00.00.01.31.72.5ENOVEnovis2.9051 of 5 stars3.42.00.00.01.91.71.9ESTAEstablishment Labs2.6063 of 5 stars3.42.00.00.02.62.50.6SNNSmith & Nephew SNATS3.0138 of 5 stars1.03.02.50.02.70.04.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 0.00N/AN/AN/AENOVEnovis 2.80Moderate Buy$58.0079.68% UpsideESTAEstablishment Labs 2.80Moderate Buy$52.4028.31% UpsideSNNSmith & Nephew SNATS 2.00Hold$28.00-7.28% DownsideCurrent Analyst Ratings BreakdownLatest ENOV, ESTA, AVNS, and SNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.005/16/2025ESTAEstablishment LabsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$62.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$48.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/1/2025SNNSmith & Nephew SNATSCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$27.00 ➝ $28.004/25/2025SNNSmith & Nephew SNATSHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/25/2025SNNSmith & Nephew SNATSHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold4/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.82$11.79 per share1.03$18.03 per share0.67ENOVEnovis$2.11B0.87$19.33 per share1.67$45.10 per share0.72ESTAEstablishment Labs$166.02M7.11N/AN/A$1.90 per share21.49SNNSmith & Nephew SNATS$5.81B2.28$3.19 per share9.47$12.04 per share2.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$8.37N/A7.02N/A-55.80%6.26%4.63%7/30/2025 (Estimated)ENOVEnovis-$825.49M-$13.95N/A10.12N/A-37.65%5.99%3.44%8/6/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)SNNSmith & Nephew SNATS$412M$2.1613.9815.100.92N/AN/AN/A8/5/2025 (Estimated)Latest ENOV, ESTA, AVNS, and SNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million5/6/2025Q1 2025AVNSAVANOS MEDICAL$0.19$0.26+$0.07$0.14$161.75 million$167.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$0.892.95%N/A41.20%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.571.56ENOVEnovis0.522.551.32ESTAEstablishment Labs5.723.362.05SNNSmith & Nephew SNATS0.622.891.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%ENOVEnovis98.45%ESTAEstablishment Labs72.91%SNNSmith & Nephew SNATS25.64%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%ENOVEnovis2.70%ESTAEstablishment Labs11.09%SNNSmith & Nephew SNATS1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.24 million45.02 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableESTAEstablishment Labs1,01828.92 million25.71 millionOptionableSNNSmith & Nephew SNATS17,349437.97 million433.59 millionOptionableENOV, ESTA, AVNS, and SNN HeadlinesRecent News About These CompaniesSNN Expands Orthopedic Portfolio With Advanced Tibia Nailing SystemJune 26 at 11:55 AM | zacks.comSNN vs. GEHC: Which Stock Is the Better Value Option?June 25 at 12:41 PM | zacks.comIs Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?June 25 at 10:41 AM | zacks.comSmith & Nephew SNATS (NYSE:SNN) Sees Unusually-High Trading Volume - Time to Buy?June 24 at 2:53 PM | marketbeat.comSmith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fracturesJune 24 at 10:00 AM | globenewswire.comScharf Investments LLC Sells 555,004 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)June 23, 2025 | marketbeat.comAjay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy OfficerJune 23, 2025 | globenewswire.comSmith+Nephew Stock May Gain From Strategic Deal With Standard HealthJune 20, 2025 | zacks.comSmith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UKJune 18, 2025 | globenewswire.comSmith & Nephew plc (NYSE:SNN) Sees Significant Increase in Short InterestJune 16, 2025 | marketbeat.comLorne Steinberg Wealth Management Inc. Boosts Position in Smith & Nephew plc (NYSE:SNN)June 16, 2025 | marketbeat.comPark Avenue Securities LLC Acquires Shares of 9,206 Smith & Nephew plc (NYSE:SNN)June 16, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Given Average Recommendation of "Hold" by BrokeragesJune 14, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Shares Purchased by GAMMA Investing LLCJune 13, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes Position in Smith & Nephew plc (NYSE:SNN)June 10, 2025 | marketbeat.comNew medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatilityJune 9, 2025 | globenewswire.comClean Yield Group Sells 150,568 Shares of Smith & Nephew plc (NYSE:SNN)June 8, 2025 | marketbeat.comSmith & Nephew (SN) Receives a Buy from CitiJune 7, 2025 | theglobeandmail.comSmith & Nephew plc (NYSE:SNN) Shares Purchased by NBC Securities Inc.June 6, 2025 | marketbeat.comSmith & Nephew plc (NYSE:SNN) Short Interest Up 22.9% in MayJune 4, 2025 | marketbeat.comBank of America Corp DE Sells 266,704 Shares of Smith & Nephew plc (NYSE:SNN)June 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthDarden Stock Set to Sizzle After Blowout Q4 and $1B BuybackBy Thomas Hughes | June 23, 2025View Darden Stock Set to Sizzle After Blowout Q4 and $1B BuybackENOV, ESTA, AVNS, and SNN Company DescriptionsAVANOS MEDICAL NYSE:AVNS$12.14 -0.13 (-1.02%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$12.17 +0.02 (+0.20%) As of 06/26/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Enovis NYSE:ENOV$32.28 +0.15 (+0.47%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$32.26 -0.02 (-0.05%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Establishment Labs NASDAQ:ESTA$40.84 +3.34 (+8.91%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$37.47 -3.37 (-8.25%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Smith & Nephew SNATS NYSE:SNN$30.20 +0.30 (+1.00%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$30.31 +0.11 (+0.37%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
